Short communication: Prevalence of HIV-1 transmitted drug resistance in Liberia

AIDS Research and Human Retroviruses

Volumn 30, Issue 9, 2014, Pages 863-866

  Loubet, Paul ^a,b   Charpentier, Charlotte ^b,c,d   Visseaux, Benoit ^b,c,d   Nuta, Cecilia ^e   Adu, Eric ^e   Chapplain, Jean Marc ^f   Baysah, Maima ^g   Walters Doe, Sylvia ^e   Tattevin, Pierre ^f   Peytavin, Gilles ^b,c,d   Yazdanpanah, Yazdan ^b,c,d   Descamps, Diane ^b,c,d  

^a Ensemble Pour Une Solidarité Thérapeutique en Réseau GIP ESTHER   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d BICHAT HOSPITAL   (France)

^e John F Kennedy Medical Center   (Liberia)

^f RENNES UNIVERSITY HOSPITAL   (France)

^g Redemption Hospital   (Liberia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANTIVIRAL RESISTANCE; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED;

EID: 84906914812     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0089     Document Type: Article

References (14)

1. UNAIDS: www.unaids.org/en/media/unaids/contentassets/documents/ unaidspublication/2013/JC2571-AIDS-by-the-numbers-en.pdf.
2. Tebit DM, Sangaré L, Tiba F, et al: Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-näve patients in Burkina Faso. J Med Virol 2009;81:1691-1701.
3. Toni T, Masquelier B, Minga A, et al.: HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: A 4-year survey, 2002-2006. AIDS Res Hum Retroviruses 2007;23:1155-1160.
4. Eshleman SH, Laeyendecker O, Parkin N, et al.: Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009; 23:845-852.
5. Hamers RL, Siwale M, Wallis CL, et al.: HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010;55:95-101.
6. Charpentier C, Bellecave P, Cisse M, et al.: High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger. Antivir Ther 2011;16: 429-433.
7. Derache A, Traore O, Koita V, et al.: Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther 2007;12: 123-129.
8. Gupta RK, Jordan MR, Sultan BJ, et al.: Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resourcelimited settings: A global collaborative study and metaregression analysis. Lancet 2012;380:1250-1258.
9. Liberia demographic and health survey 2007 (Liberia demographic and health survey 2007.pdf).
10. Bennett DE, Camacho RJ, Otelea D, et al.: Drug resistance mutations for surveillance of transmitted HIV-1 drugresistance: 2009 update. PLoS One 2009;4:e4724.
11. Jung BH, Rezk NL, Bridges AS, Corbett AH, and Kashuba AD: Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007;21:1095-1104.
12. Johnson JA, Li JF, Wei X, et al.: Minority HIV-1 drug resistance mutations are present in antiretroviral treatmentna ̈ve populations and associate with reduced treatment efficacy. PLoS Med 2008;5:e158.
13. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, and Gilks CF: Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008;13(Suppl 2):25-36.
14. Hamers RL, Wallis CL, Kityo C, et al.: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011;11: 750-759.